Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, Ph.D., present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference on March 9, 2021, starting at 7:00 am ET. The presentation will focus on Keros' advancements in treatments for hematological and musculoskeletal disorders. Investors can access the live presentation and subsequent replays for 90 days via the company’s website.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 1:40 PM ET. The presentation will be available via live webcast and archived for 90 days on Keros's website. Keros is focused on developing innovative treatments for hematological and musculoskeletal disorders, including KER-050 for cytopenias, KER-047 for iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced its addition to the NASDAQ Biotechnology Index, effective before market open on December 21, 2020. This index tracks biotechnology and pharmaceutical companies listed on Nasdaq. Keros specializes in developing treatments for hematological and musculoskeletal disorders, notably its lead candidates KER-050 for cytopenias and KER-047 for iron imbalance-related anemia. The company's work addresses significant unmet medical needs in these areas, showcasing its potential for growth and innovation in the biopharmaceutical sector.
Keros Therapeutics has appointed Mary Ann Gray, Ph.D., to its Board of Directors, enhancing its leadership team. Dr. Gray brings extensive experience from her roles in biotechnology and investment, including positions at Federated Kaufmann Fund and various biotech boards. Concurrently, Alon Lazarus will step down after serving since 2016. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates addressing conditions like cytopenias and bone loss.
Keros Therapeutics, Inc. (KROS) presented data from its Phase 1 clinical trial of KER-047 at the 62nd ASH Annual Meeting, highlighting significant increases in serum iron and transferrin saturation with a corresponding decrease in ferritin and hepcidin. Preclinical data also revealed that KER-050 could alleviate anemia through various mechanisms. The Phase 1 trial showed a tolerability profile with no serious adverse events, although some mild to moderate adverse events were reported. Keros plans to initiate Phase 2 trials for both KER-050 and KER-047 in 2021.
Keros Therapeutics, Inc. (KROS) has successfully closed a public offering of 2,990,000 shares of common stock at $50.00 each, generating $149.5 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase an additional 390,000 shares. The offering was managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. The proceeds will be used to advance Keros’ clinical programs, including its lead product candidates KER-050, KER-047, and KER-012, which target hematological and musculoskeletal disorders.
Keros Therapeutics, a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, present at the Jefferies Virtual London Healthcare Conference on November 18 at 9:05 am ET. The event will be webcast live and archived on the company's website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders with high unmet medical needs, including its lead product candidates KER-050, KER-047, and KER-012, targeting conditions like anemia and osteoporosis.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced a public offering of 2,600,000 shares at $50.00 each, aiming to raise $130 million before expenses. The offering, managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co., is set to close on November 17, 2020. The company also granted underwriters a 30-day option for an additional 390,000 shares. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with lead candidates including KER-050 and KER-047 targeting conditions like anemia and bone loss.
Keros Therapeutics (Nasdaq: KROS) announced a proposed underwritten public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. Pricing details are yet to be determined, as the offering is subject to market conditions. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. are managing the offering, while a registration statement has been filed with the SEC but is not yet effective. Keros focuses on developing treatments for hematological and musculoskeletal disorders.
Keros Therapeutics (KROS) reported Q3 2020 financial results and a business update, achieving a milestone by dosing first patients in its Phase 2 clinical trial for KER-050, targeting myelodysplastic syndromes. The company regained worldwide rights to metabolic disease programs following the termination of its collaboration with Novo Nordisk, effective April 2021. Keros reported a net loss of $12.0 million for Q3 2020, up from $3.5 million in Q3 2019, driven by increased R&D and administrative expenses. Cash reserves at the end of Q3 stood at $133.8 million, projected to sustain operations into late 2022.